What is the clinical effect of budesonide sustained-release capsules?

Budesonide extended-release capsules, as a highly effective corticosteroid, have demonstrated significant efficacy in the treatment of mild to moderate active Crohn's disease in the ileum and/or ascending colon. Crohn's disease, a chronic inflammatory bowel disease, is often accompanied by symptoms such as diarrhea, abdominal pain, and weight loss, which seriously interferes with patients' daily life. The emergence of budesonide sustained-release capsules has brought a new treatment option to patients with Crohn's disease.

In-depth exploration of clinical research has fully verified the excellent efficacy of budesonide sustained-release capsules. In an 8-week, randomized, double-blind, controlled trial, budesonide extended-release capsules were compared head-to-head with placebo or other treatments. The results showed that budesonide sustained-release capsules performed well in reducing the Crohn's disease activity index (CDAI) and significantly improved the patients' clinical symptoms. Specifically, the clinical improvement rate of the budesonide sustained-release capsule group at a daily dose of 9 mg was far higher than that of the placebo group, which strongly proves its significant effect in the treatment of Crohn's disease.

Not only that, budesonide sustained-release capsules also show their unique advantages in terms of safety and tolerability. Compared with other glucocorticoid drugs, budesonide sustained-release capsules have significantly fewer systemic side effects, allowing patients to use this drug with greater peace of mind and longer, thereby better controlling their disease and improving their quality of life.

It is worth mentioning that budesonide sustained-release capsules have a wide range of applications, not only for adult patients, but also provide effective treatment options for pediatric patients8 years old and above. In clinical studies on pediatric patients, budesonide sustained-release capsules also demonstrated impressive efficacy and safety, bringing hope of recovery to more young patients.

In addition, budesonide extended-release capsules also play a pivotal role in maintaining clinical remission. A 12-month randomized double-blind study showed that the drug can significantly extend the patient's relapse time, reduce the risk of symptoms losing control, and provide patients with a more long-term and stable disease control effect.

To sum up, budesonide sustained-release capsules have become an important choice for the treatment of mild to moderate active Crohn's disease in the ileum and/or ascending colon due to its significant efficacy, good safety, wide range of application and long-term stable disease control effect.

Reference: https://www.drugs.com/pro/entocort-ec.html#s-34090-1